Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceritinib

FDA-approved product (capsule, oral), marketed as Zykadia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ceritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

    NCT02729961 · start 2018-01-03

    Registered record
    Registry ID
    NCT02729961
    Conditions
    Anaplastic Large Cell Lymphoma, ALK-Positive; CD30-Positive Neoplastic Cells Present; Systemic Anaplastic Large Cell Lymphoma
    Interventions
    Brentuximab Vedotin; Ceritinib; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-01-03
    Completion
    2023-07-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma, ALK-Positive; CD30-Positive Neoplastic Cells Present; Systemic Anaplastic Large Cell Lymphoma
    InterventionBrentuximab Vedotin; Ceritinib; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    NCT03087448 · start 2017-09-09

    Registered record
    Registry ID
    NCT03087448
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Ceritinib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-09-09
    Completion
    2022-04-30
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionCeritinib; Trametinib
    PhasePhase 1
    Registry statusTerminated

  • Next Generation Personalized Neuroblastoma Therapy

    NCT02780128 · start 2016-07

    Registered record
    Registry ID
    NCT02780128
    Conditions
    Neuroblastoma; Cancer
    Interventions
    Biopsy; Next Generation Sequencing; Tumor Scans; Bone marrow Tests; Physical Exam; Eye Exam; Labs; Pregnancy Test; Interviews; ECG; Echocardiogram; Ribociclib; Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-07
    Completion
    2022-08
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Cancer
    InterventionBiopsy; Next Generation Sequencing; Tumor Scans; Bone marrow Tests +9 more
    PhasePhase 1
    Registry statusTerminated

  • Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

    NCT02321501 · start 2016-06-22

    Registered record
    Registry ID
    NCT02321501
    Conditions
    ALK Positive; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; ROS1 Gene Rearrangement; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions
    Ceritinib; Everolimus; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-06-22
    Completion
    2026-12-31
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; ROS1 Gene Rearrangement +2 more
    InterventionCeritinib; Everolimus; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 1
    Registry statusActive not recruiting

  • Ceritinib Rare Indications Study in ALK+ Tumors

    NCT02465528 · start 2016-05-06

    Registered record
    Registry ID
    NCT02465528
    Conditions
    Tumors With Aberrations in ALK; Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumor; Glioblastoma
    Interventions
    Ceritinib (LDK378)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-05-06
    Completion
    2018-08-20
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors With Aberrations in ALK; Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumor; Glioblastoma
    InterventionCeritinib (LDK378)
    PhasePhase 2
    Registry statusTerminated

  • Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

    NCT02584933 · start 2015-12-11

    Registered record
    Registry ID
    NCT02584933
    Conditions
    ALK Positive Malignancies
    Interventions
    ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2015-12-11
    Completion
    2027-06-09
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive Malignancies
    Interventionceritinib
    PhasePhase 4
    Registry statusActive not recruiting

  • Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

    NCT02638909 · start 2015-12

    Registered record
    Registry ID
    NCT02638909
    Conditions
    Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Adenocarcinoma
    Interventions
    ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2018-03-29
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma +2 more
    Interventionceritinib
    PhasePhase 2
    Registry statusTerminated

  • Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

    NCT02513667 · start 2015-11

    Registered record
    Registry ID
    NCT02513667
    Conditions
    ALK-positive Non-small Cell Lung Cancer
    Interventions
    Ceritinib; Stereotactic ablative body radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2021-05-29
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small Cell Lung Cancer
    InterventionCeritinib; Stereotactic ablative body radiation
    PhasePhase 2
    Registry statusTerminated

  • A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

    NCT02422589 · start 2015-10-23

    Registered record
    Registry ID
    NCT02422589
    Conditions
    ALK-positive Advanced Tumors
    Interventions
    ceritinib; warfarin; midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10-23
    Completion
    2017-12-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Advanced Tumors
    Interventionceritinib; warfarin; midazolam
    PhasePhase 1
    Registry statusCompleted

  • Genomic Landscape of Ceritinib

    NCT02554591 · start 2015-09-16

    Registered record
    Registry ID
    NCT02554591
    Conditions
    Carcinoma, Non-Small-Cell Lung; Non-small Lung Cancer; Non-Small Cell Lung Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2015-09-16
    Completion
    2018-02-28
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Non-small Lung Cancer; Non-Small Cell Lung Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    NCT02559778 · start 2015-09

    Registered record
    Registry ID
    NCT02559778
    Conditions
    Neuroblastoma
    Interventions
    Ceritinib; dasatinib; sorafenib; vorinostat; DFMO
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2015-09
    Completion
    2035-09
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionCeritinib; dasatinib; sorafenib; vorinostat +1 more
    PhasePhase 2
    Registry statusRecruiting

  • LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

    NCT02450903 · start 2015-08-21

    Registered record
    Registry ID
    NCT02450903
    Conditions
    Non-Small-Cell Lung Cancer
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08-21
    Completion
    2018-05-24
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Cancer
    InterventionLDK378
    PhasePhase 2
    Registry statusCompleted

  • Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

    NCT02289144 · start 2015-06

    Registered record
    Registry ID
    NCT02289144
    Conditions
    Metastatic Anaplastic Thyroid Cancer; Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
    Interventions
    Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-06
    Completion
    2019-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Anaplastic Thyroid Cancer; Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
    InterventionCeritinib
    PhasePhase 2
    Registry statusWithdrawn

  • Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

    NCT02393625 · start 2015-05-27

    Registered record
    Registry ID
    NCT02393625
    Conditions
    ALK-positive NSCLC
    Interventions
    Ceritinib (LDK378); Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2015-05-27
    Completion
    2027-04-09
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive NSCLC
    InterventionCeritinib (LDK378); Nivolumab
    PhasePhase 1
    Registry statusActive not recruiting

  • Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

    NCT02292550 · start 2015-05-14

    Registered record
    Registry ID
    NCT02292550
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Ribociclib; Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-05-14
    Completion
    2018-09-26
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionRibociclib; Ceritinib
    PhasePhase 1
    Registry statusCompleted